Latest Roche Stories

PRINCETON, N.J., Aug. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended June 30, 2009. Financial Results Revenues were $10.5 million during the quarter ended June 30, 2009 compared to $0.5 million for the quarter ended June 30, 2008 and reflect the receipt...

BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per share, compared with a net loss of $29.6 million, or $0.76 per share, in the second quarter of 2008. Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The last several months have been...

Zdechlik was Founding member of the U.S. Clinical Molecular Diagnostic GroupNEW YORK, July 23 /PRNewswire-USNewswire/ -- Exosome Diagnostics, Inc., the developer of non-invasive molecular oncology diagnostics to aid in early cancer detection and therapeutic selection, announced today that Greg Zdechlik has been named Chief Operating Officer. As COO, Zdechlik will be responsible for driving diagnostic development, commercial relations, and product introduction including Exosome's new blood...

Program helps diabetes educators better engage and motivate their patients with the goal of more positive outcomes. INDIANAPOLIS, June 30 /PRNewswire/ -- Roche, the maker of ACCU-CHEK blood glucose monitoring systems and insulin pumps, announced today the latest component of its Behavior Change through Patent Engagement (sm) program. Creative Coaching is an advanced educational program that fights the growing epidemic of diabetes by improving dialogue between diabetes educators and their...

- Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 9 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) (tocilizumab), a novel interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate,...

Roche to fund evaluation of Raptor's proprietary NeuroTrans(TM) technology NOVATO, Calif., June 9 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has entered a collaboration and licensing agreement with Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) to evaluate therapeutic delivery across the blood-brain barrier, ("BBB") starting with Raptor's proprietary NeuroTrans(TM) BBB transporter platform. Under terms of...

Preclinical Data Reported by Roche at 69th Scientific Sessions SAN FRANCISCO, June 4 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that preclinical data related to diacylglycerol acyl transferase - 1 (DGAT1) inhibitors will be presented in a poster presentation at the 69th Scientific Sessions of the American Diabetes Association...

- Results of Phase III clinical studies highlight benefits of ACTEMRA as a treatment for rheumatoid arthritis - NUTLEY, N.J., June 4 /PRNewswire/ -- Roche today announced that oral and poster presentations highlighting results from the extensive multi-national ACTEMRA(R) (tocilizumab) clinical development program will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark. The studies...

People with diabetes can improve their general health and self-care management by using simple tools to uncover links between lifestyle and blood glucose levels. INDIANAPOLIS, May 28 /PRNewswire/ -- Roche, the maker of ACCU-CHEK(R) blood glucose monitoring systems and insulin pumps, announced today the availability of two new tools that can help patients pinpoint food and lifestyle choices that have the biggest impact on their blood glucose levels, giving them greater control in their...

WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. The SEARCH (Sorafenib and...